Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metabolic disorders
Biotech
Cardiometabolic field drives M&A while cancer deals drop: report
Cardiovascular and metabolic deals have risen sharply, while cancer M&A activity has dropped, especially in targeted oncology and IO non-cell spaces.
Gabrielle Masson
Oct 27, 2025 2:39pm
Arrowhead sues Ionis over patent dispute for Tryngolza rival
Sep 11, 2025 11:33am
FDA considers new liver trial endpoint, sending MASH shares up
Aug 28, 2025 11:25am
Novo seeks obesity refresh with $550M Replicate deal
Aug 28, 2025 7:00am
Terns vows to stop funding metabolic disease trials beyond 2025
Aug 6, 2025 6:20am
Sanofi pens $395M China pact for Arrowhead metabolic med
Aug 1, 2025 7:21am
